Virbac Stock Rises Nearly 2% and Crosses a Technical Threshold
The veterinary laboratory in Carros recovers mid-morning in a well-oriented Parisian market. The stock regains ground above a short-term technical reference after several sessions of consolidation around its moving averages.
A Rebound Bringing the Price Above the 20-Day Moving Average in a Supportive Market
Virbac stock gains 1.57% to €356.50, up from €351 the previous day. Meanwhile, the SBF 120 index is up by 0.33% and the CAC 40 by 0.32%. The stock ranks high in the broad index but does not feature among the session's most significant gains. The rebound brings the price just above the 20-day moving average, at €353.73, a mark it fell below at the end of May. The 50-day moving average at €359.76 remains slightly above the current price and represents the next short-term hurdle, while the 200-day moving average (€348.79) provides substantial support, with the stock trading 2.2% above it. The RSI at 46 indicates a neutral setup, consistent with a breathing movement after a monthly decline of 1.66%.
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Year-on-year, Virbac maintains a gain of 8.19%, and the three-month performance remains positive at 2%. The recent sequence is more turbulent: -0.97% over the week and -1.66% over thirty days, following the peak of €369 on May 21, when TP Icap had raised its target to €412. Since then, the stock has retreated about 3% and has been trading between its support at €339 and resistance at €378.50. The one-month volatility remains contained at 7.33, which aligns with the absence of any specific catalyst for the group this Friday. The next technical marker to watch is the 50-day moving average, crossing which could open the way to the €369-378.50 zone tested in mid-May.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 1 168 millions d'euros
Quarterly revenue: 1 168 millions d'euros
Guidance from the release
Notre solide performance à fin septembre 2026 nous permet de viser le haut de notre fourchette initiale de croissance du chiffre d'affaires
Risks mentioned
Effets de change défavorables impactant la croissance réelle (croissance réelle +5,9% vs +7,9% à taux constants)
Pression concurrentielle persistante sur les vaccins porcins en Asie de l'Est et pressions tarifaires au segment Animaux d'élevage
Exposition au Moyen-Orient et suivi des tendances inflationnistes (énergie) malgré anticipation d'impacts limités
Opportunities identified
Croissance soutenue des plateformes Supercharge (+11% environ) couvrant petfood, reproduction, dentaire, mobilité, otologie, endocrinologie et ruminants
Intégration fluide de Thyronorm dans la franchise d'endocrinologie avec contribution de +1 point de croissance et +0,5 point d'Ebit ajusté
Redémarrage réussi de la production du contrat majeur de façonnage en Amérique du Nord (juillet 2026) après contrainte réglementaire temporaire
Outlook / guidance
Expected revenue: 1 575 millions d'euros
Management commentary: « Bien que nos perspectives pour l'ensemble de l'année 2026 restent inchangées, notre solide performance à fin septembre (croissance de +7,9%) nous permet de viser la borne haute de notre fourchette de croissance du chiffre d'affaires de 5,5 % à 7,5 % à PCC »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
